These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1826740)

  • 1. Publication of unethical studies on the treatment of chemotherapy-induced emesis.
    Roila F; Tonato M; Del Favero A
    J Clin Oncol; 1991 May; 9(5):891-3. PubMed ID: 1826740
    [No Abstract]   [Full Text] [Related]  

  • 2. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
    Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
    J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ondansetron vs dexamethasone for chemotherapy-induced emesis.
    Lancet; 1991 Aug; 338(8765):478-9. PubMed ID: 1714531
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes.
    Schmoll HJ
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S35-9. PubMed ID: 2533897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ondansetron: a new entity in emesis control.
    Graves T
    DICP; 1990 Nov; 24(11 Suppl):S51-4. PubMed ID: 2148659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New antiemetic effective for cisplatin-induced emesis.
    Oncology (Williston Park); 1989 Jul; 3(7):79. PubMed ID: 2534945
    [No Abstract]   [Full Text] [Related]  

  • 7. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of chemotherapy-related nausea and vomiting using a serotonin antagonist.
    Egan AP; Taggart JR; Bender CM
    Oncol Nurs Forum; 1992 Jun; 19(5):791-5. PubMed ID: 1535124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral ondansetron (GR38032F) for the control of acute and delayed cyclophosphamide-induced emesis.
    Rosso R; Campora E; Cetto G; Fosser V; Marangolo M; Oliva C
    Anticancer Res; 1991; 11(2):937-9. PubMed ID: 1829602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
    Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
    J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting.
    Burnette PK; Perkins J
    Pharmacotherapy; 1992; 12(2):120-31. PubMed ID: 1533280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
    Kris MG; Tyson LB; Clark RA; Gralla RJ
    Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.
    Mitchell PL; Evans BD; Allan SG; Forgeson GV; Mak D; Neave L; Humm G; Langley G; Dickson D; Harvey VJ
    N Z Med J; 1992 Mar; 105(929):73-5. PubMed ID: 1532054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia.
    Carden PA; Mitchell SL; Waters KD; Tiedemann K; Ekert H
    J Clin Oncol; 1990 Sep; 8(9):1531-5. PubMed ID: 2144019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emesis as a complication of cancer chemotherapy: pathophysiology, importance, and treatment.
    Graves T
    Pharmacotherapy; 1992; 12(4):337-45. PubMed ID: 1387707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ondansetron to prevent chemotherapy-induced vomiting.
    Drug Ther Bull; 1992 Mar; 30(6):21-3. PubMed ID: 1534293
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral treatment with ondansetron in an outpatient setting.
    Dicato MA
    Eur J Cancer; 1991; 27 Suppl 1():S18-9; discussion S22. PubMed ID: 1831630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ondansetron: A new concept in the management of emesis. Proceedings from an investigators meeting. Seattle, Washington, September 1990.
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):1-78. PubMed ID: 1387244
    [No Abstract]   [Full Text] [Related]  

  • 19. Ondansetron and cisplatin-induced nausea and vomiting.
    Hait WN
    N Engl J Med; 1990 Nov; 323(21):1485-6. PubMed ID: 2146502
    [No Abstract]   [Full Text] [Related]  

  • 20. Ondansetron in the treatment of theophylline overdose.
    Brown SG; Prentice DA
    Med J Aust; 1992 Apr; 156(7):512. PubMed ID: 1532627
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.